SURAKSHA

- Suraksha Diagnostic Limited will hold its 21st Annual General Meeting (AGM) on Tuesday, September 22, 2026, at 11:30 A.M. (IST) via Video Conference/OAVM. - The Annual Report for FY 2025-26 is available on the company's website and stock exchange websites. - Record Date for Dividend: September 15, 2026. - Remote e-voting period: September 18, 2026 (9:00 A.M.) to September 21, 2026 (5:00 P.M.).

- Q1 FY27 Consolidated Revenue growth of 21% YoY, EBITDA growth of 28% YoY, and PAT growth of 40% YoY. - EBITDA margin expanded to 36% in Q1 FY27 from 34% in Q1 FY26, with PAT margin at 14.7%. - Genomics business revenue grew 136% YoY to ₹13.7 million, with no major additional CapEx needed in the next 2-3 years. - Mature centres achieved 40.9% EBITDA margin; new centres (under 2 years old) turned profitable with 6.5% EBITDA margin. - Management expects overall EBITDA margin not to fall below 34% in FY27 and aims for 33-34% by FY28-29. - Guided for around 20% quarterly growth for FY27 and is on track to open 100 centres by FY28. - Capex outlook for FY27 is ₹70-80 crores, with plans to add 3 hubs and 6 spokes during the year, alongside expansion into Jharkhand and Tripura. - Q2 FY27 is expected to be a strong quarter, with July and August trends looking robust.

New Filing detected. See link for details.

- Audio recording of the Earnings Call held on August 13, 2026, discussing the unaudited financial results for the quarter ended June 30, 2026, is now available on the company's website.

- Audio recording of the Earnings Call held on August 13, 2026, at 11:30 a.m. IST, discussing the unaudited financial results for the quarter ended June 30, 2026, is now available on the company's website.

- Q1 FY27 Consolidated Revenue ₹88.73 Cr vs Q1 FY26 ₹73.49 Cr (▲20.7% YoY) - EBITDA ₹31.53 Cr vs ₹24.66 Cr (▲27.9% YoY) - PAT ₹12.85 Cr vs ₹9.18 Cr (▲40.0% YoY) - EBITDA Margin 36.0% vs 34.0% (▲200bps)

- Q1 FY27 Consolidated Revenue from Operations ₹876.45 Mn vs ₹725.86 Mn (▲20.75% YoY) - EBITDA ₹315.3 Mn vs ₹246.56 Mn (▲27.9% YoY) - PAT ₹128.45 Mn vs ₹91.75 Mn (▲40.0% YoY) - EBITDA Margin 36.0% vs 34.0% (▲200bps)

- Q1 FY27 Consolidated Revenue ₹87.65Cr vs ₹72.59Cr (▲20.75% YoY) - EBITDA ₹30.44Cr vs ₹23.75Cr (▲28.18% YoY) - PAT ₹12.85Cr vs ₹9.18Cr (▲40.00% YoY) - EBITDA Margin 34.73% vs 32.72% (▲201bps) - The Board approved the appointment of Mr. Dinesh Gupta as Chief Financial Officer (CFO) with effect from August 24, 2026. - The Board fixed September 15, 2026, as the Record Date for determining dividend entitlement for the financial year ended March 31, 2026.

- Q1 FY27 Consolidated Revenue ₹87.65 Cr vs ₹72.59 Cr (▲20.75% YoY) - EBITDA ₹30.44 Cr vs ₹23.75 Cr (▲28.18% YoY) - PAT ₹12.85 Cr vs ₹9.18 Cr (▲40.00% YoY) - EBITDA Margin 34.73% vs 32.72% (▲201bps) - Board approved the appointment of Mr. Dinesh Gupta as Chief Financial Officer and Group Chief Financial Officer, effective August 24, 2026. - Fixed September 15, 2026, as the Record Date for determining the dividend entitlement for the financial year ended March 31, 2026. - The company has provisioned ₹81.16 lakhs for an ongoing dispute with the Government of Meghalaya concerning a step-down subsidiary, which has resulted in operational losses.

- Q1 FY27 Consolidated Revenue ₹87.65Cr vs ₹72.59Cr (▲20.7% YoY) - EBITDA ₹30.44Cr vs ₹23.75Cr (▲28.2% YoY) - PAT ₹12.85Cr vs ₹9.18Cr (▲40.0% YoY) - EBITDA Margin 34.73% vs 32.72% (▲201bps) - Board recommended dividend for the financial year ended 31 March 2026, with a record date of September 15, 2026.

- Q1 FY27 Consolidated Revenue ₹8,764.54 lakhs vs ₹7,258.63 lakhs (▲21% YoY) - EBITDA ₹3,044.24 lakhs vs ₹2,375.03 lakhs (▲28% YoY) - PAT ₹1,284.54 lakhs vs ₹917.51 lakhs (▲40% YoY) - EBITDA Margin 34.7% vs 32.7% (▲200bps) - Board approved the appointment of Mr. Dinesh Gupta as Chief Financial Officer with effect from August 24, 2026. - The company fixed September 15, 2026 as the Record Date for dividend entitlement for FY2025-26. - A dispute in a step-down subsidiary with the Government of Meghalaya resulted in operational losses; arbitration is ongoing. Management made a provision of ₹81.16 lakhs.

- Postponement of the 21st Annual General Meeting (AGM) originally scheduled for September 02, 2026. - Due to certain unavoidable circumstances. - Revised date, time, and venue will be informed in due course.

- Concall Schedule - Concall Date: Thursday, 13 August, 2026 - Concall Time: 11:30 A.M. (IST) - Purpose: Discussion on Q1 FY27 financial results

- Trading window closed from July 01, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026.

- Ms. Mamta Jain resigned from the position of Company Secretary & Compliance Officer and Key Managerial Personnel (KMP) of Suraksha Diagnostic Limited. - Her last working day with the Company will be 15 July 2026. - The resignation is due to personal reasons.